DHX디에이치엑스컴퍼니

Quick answers about DHX

What does DHX do?

DHX Company (디에이치엑스컴퍼니) is a Korean holding company whose subsidiaries operate in bicycles, ICT distribution, bio-medical products, property agency services, food processing and advertising. Its main revenue comes from distributing computers and peripherals in Korea, along with distribution of F&B, cosmetics and e-cigarettes and regional specialty products, sold through direct sales, online channels and large retailers. The bio segment develops and sells medical devices such as the Hemapure blood-treatment device and the NeuroHarmony AI brain diagnostic device, a pain-treatment drug called Apitoxin, and skin microbiome-based products, and the company operates primarily in South Korea with some exports.

What is the market cap of DHX?

The market capitalisation of DHX was ₩19B at the close on Oct 30, 2026.

Who are the largest shareholders of DHX?

According to the latest official filings, the largest reported holders are BF Labs (31.25%, as of Jul 8, 2025); Prime Core (29.70%, as of Apr 15, 2026); Daeheung Central Industry Development Investment (16.85%, as of Jan 30, 2026).

When is the next earnings report from DHX?

Korean companies rarely announce results dates in advance. Based on when DHX filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.